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Abstract
Hypertrophic cardiomyopathy (HCM) is a dominant genetic disorder of the myocardium
associated with dysfunctional contractile proteins. The major risk of HCM is sudden cardiac
death, which may occur even in asymptomatic carriers. Causes are highly heterogeneous.
Over 140 different mutations in nine sarcomeric genes have been described to date. The
majority of cases (80% or more) may eventually be traced to one of these genes. Although
genetic counselling is suggested even if mutations are not known, molecular diagnosis
implies new options such as carrier identification or — theoretically — preclinical risk
stratification. A scheme according to which cardiologists and clinical and molecular
geneticists could cooperate in counselling patients and managing HCM clinically is proposed.
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Introduction
A young boy of 13 collapsed while running after the
schoolbus. He could be resuscitated, but at the price of
crippling brain damage. Clinical and genetic analysis sub-
sequently revealed that he and his father were predis-
posed to hypertrophic cardiomyopathy (HCM): they were
carriers of a missense mutation in the a-tropomyosin gene.
The boy had no symptoms before he collapsed, whereas
his father (in his early forties) had borderline myocardial
hypertrophy in the interventricular septum associated with
mild symptoms of cardiac disease. A daughter, age 11,
also carried the mutation, but she was entirely asympto-
matic. On average, penetrance of the disease gene was
incomplete in this family. The boy’s collapse was presum-
ably due to an episode of extreme ventricular tachycardia.
Although the familial character of the disorder was sus-
pected for some time prior to this event, genetic coun-
selling had not been considered before the boy
experienced cardiac arrest.
In a second family the disease was associated with a high
frequency of cardiac death. Three documented cases of
premature sudden death in two generations, two of them
in young adults, and numerous relatives being clinically
affected imposed a heavy burden on the family. Early
onset of the disease, syncopes, chest pain and progres-
sion to heart failure with no, or inconspicuous, hypertrophy
were encountered. A few patients were only mildlyCurrent Controlled Trials in Cardiovascular Medicine    Vol 1 No 1 Vosberg
affected. A mutation in the cardiac troponin T gene was
identified by genetic analysis. All first-degree relatives of
the patients were seeking counselling and asked for a
DNA test. They were aware that this test offered a 50%
chance of excluding the carrier status for those who were
asymptomatic, in particular for children of parents at risk.
Hence, parents also asked on behalf of their children.
These are two different disease phenotypes randomly
picked from numerous published or unpublished case
reports of familial HCM. This is a heavily investigated dis-
order for which we have ample knowledge about causes
and — to a lesser degree — about mechanisms. It is auto-
somal dominant and known to exist worldwide with a
prevalence possibly as high as 1:500 in the general popu-
lation [1]. It may occur sporadically, but in the majority of
cases it is a familial condition. Onset of symptoms is nor-
mally encountered during adolescence or in young adults,
but first appearances may also be experienced in later
decades of life. Symptoms are usually unspecific at first,
and may include breathlessness, chest pain, syncopes
and others. The diagnosis is confirmed by echocardio-
graphic demonstration of myocardial hypertrophy, most
frequently in the interventricular septum. Diagnostic crite-
ria for the assessment of the disease in members of fami-
lies at risk have been proposed [2].
Causes and mechanisms
A major dysfunction in cardiac performance is impaired
relaxation during diastole. Systolic functions are (at least in
the beginning) not affected [3]. The most serious compli-
cation of HCM is ventricular fibrillation, which may cause
sudden cardiac death.
A typical problem is the extensive clinical variability of
HCM, even within families where all patients have the
same mutational background. The spectrum ranges from
very mild or even asymptomatic to malignant courses. A
multitude of causes has been identified. More than 100
different mutations (mostly missense mutations leading to
amino acid exchanges in respective proteins) have been
reported [4,5]. These mutations are in nine genes, all
coding for contractile proteins — cardiac motor proteins
and their control components. HCM was, therefore,
defined as a disease of the sarcomere [6]. The most fre-
quently affected genes, accounting for more than 50% of
all cases, coded for b-myosin heavy chain, cardiac tro-
ponin T and myosin binding protein-C. Mutational hot
spots are rare and contribute only a few percent of the
total genetic load of HCM.
The mechanisms responsible for cardiac dysfunction and
disease are not fully understood. Altered kinetics of cross-
bridge cycling of myosin and actin filaments are probably
involved [7]. Increased (or decreased) sensitivity of force
development in response to calcium may be a critical
parameter [8,9]. Other calcium-dependent mechanisms
influencing gene expression rather than contraction have
also been discussed [10].
Diagnosis and repercussions
Since HCM is inherited, a major question bears on genetic
counselling. Is it available and what will it offer to whom?
The goals of counselling are, in general, the assessment of
causes, which requires genetic testing of probands and
family members, the determination of recurrence risks,
communication about reproductive options and prenatal
diagnosis, if suggested or requested.
The clinical diagnosis of HCM is made by the cardiologist
who might then refer patients and families to the geneti-
cist. Genetic tests are performed in specialised labs (of
which only a few exist). The estimate of recurrence risks is
easy in most instances, because the usual mode of trans-
mission is known to be dominant. Dominant transmission
(when only one parent is a carrier of the condition) means
the parent has a 50% chance of transmitting the mutation
to their offspring. Recessive transmission (with both
parents being carriers) is extremely rare. More challenging,
but also rather infrequent, are asymptomatic parents with
one affected child, a condition indicative of a new, or de
novo, mutation which originated in a single parental
gamete [11,12]. Such a mutation has a negligible chance
of re-occurring in siblings, but it can be passed to the next
generation by carriers.
HCM is in many cases not a devastating condition and
usually it does not produce symptoms in children, unlike
Duchenne muscular dystrophy or cystic fibrosis. Many
gene carriers have a reasonable chance of getting away
with minor symptoms and normal life expectancy (see eg
[13,14]); in some, however, quality of life and longevity
may be severely affected. Families have been described
where only 50% of gene carriers lived beyond the age of
45 years [15]. Although underlying mutations in these fam-
ilies are statistically characterised as malignant, it is diffi-
cult (if not impossible) to assign individual risks on the
basis of a DNA test alone. Thus, in most cases of a posi-
tive HCM family history, reproductive decisions are nor-
mally not affected.
Occasionally it may happen that premature sudden
death is a frequent event imposing an unusually high
psychosocial and medical burden on a family. In these
cases prospective parents may wish to prevent passing
the mutation to their offspring and, hence, ask for a pre-
natal DNA test with the option to terminate a ‘carrier’
pregnancy. The test depends on knowledge of the muta-
tion. If that information is not available, testing will nor-
mally be futile because of the current slow speed of
screening genes for unidentified DNA changes. If the
mutation is known, a preimplantation diagnosis after inc
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vitro fertilisation may be considered as an alternative to
prenatal testing [16].
In addition to professional counselling by geneticists, a
practice of informal communication developed in some
institutions since the main reference person for HCM
patients and their families is the cardiologist whom they
see on a regular basis to control the progression of the
disease and the efficacy of therapy. Diagnostic efforts
require informed consent by the patient; this consent fre-
quently covers the submission of blood samples to a spe-
cialised molecular lab for a DNA test, as part of a new
clinical routine which should, but which frequently does
not, include genetic counsel. This practice of quasi auto-
matic DNA testing may not be the same in all countries,
but at least in some places the geneticist is not regularly
consulted. The reason is simply that it is the cardiologist,
not the clinical geneticist, who has the main responsibility
for the patient. The recognition that a patient is at high risk
depends on identification of clinical markers such as
excessive hypertrophy [17] or nonsustained ventricular
tachycardia [18] rather than on the demonstration of a
particular mutation.
The lack of appropriate counselling has, however, certain
drawbacks. Normally it is the genetic counsellor, not the
clinician, who is trained to explain the meaning of genetic
risks in terms understandable to patients. The burden of
the disease must be clearly communicated and reproduc-
tive options have to be discussed. Reassurance should be
given to those who worry about the consequences of their
genetic status. It may be added that these discussions
should also cover health and life insurance problems which
will probably become relevant in the future, in particular for
those who have no symptoms but who are at risk to be
gene carriers. Potential gene carriers with no symptoms
may increasingly tend to refuse participation in familial
screening to avoid unfavourable terms of insurance, a con-
flict to which young adults in their early career stages are
exposed more than others. (The strategy of avoiding knowl-
edge about genetic risks would, however, only work in the
absence of compulsory testing.). A serious question is
whether DNA tests should be applied in children. They
usually have no symptoms, and the test may therefore stig-
matise them as gene carriers — in the absence of efficient
prevention ([19], but see [20]). One should realise,
however, that careful investigation of the preclinical stages
of HCM will eventually help to advance knowledge of the
natural history of the disease — a prerequisite to the devel-
opment of improved protocols for prevention and therapy
of this disorder. At present, in the absence of formal con-
straints to apply DNA tests to entire families, it can be fore-
seen and it seems inevitable that in a growing number of
families all gene carriers will become known. As a rule (with
occasional exceptions), both cardiologists and parents
want to know. Appropriate communication with genetic
counsellors should help to alleviate psychosocial and emo-
tional problems associated with the assessment of the
carrier status, in particular in the young. A scheme accord-
ing to which cardiologists, clinical and molecular geneti-
cists could cooperate in both aspects, counselling patients
and managing HCM clinically, is presented in Fig. 1. This
scheme emphasises the different branches involved in
management and counselling of HCM, with a predomi-
nance on the side of clinical activities. Prenatal diagnosis —
which in our experience is almost never requested — has
not been considered in this scheme as a major topic.
Conclusion
A DNA test can confirm the diagnosis; however, in most
cases, a sarcomeric mutation does not by itself fully explain
the pathogenic character of the disease. For one, many
families have their own ‘private’ mutation, and for another,
evidence is accumulating that other components, for
example genetic polymorphisms, which contribute to car-
diovascular performance without being bona fide disease
genes, also affect penetrance and severity of the disease. It
Figure 1
A scheme for cooperative interaction between cardiologists, clinical
and molecular geneticists and those affected by HCM. Note: Prenatal
diagnosis is not usually involved. TASH, transcoronary ablation of
septum hypertrophy (by alcohol); ICD, implantable cardioverter
defibrillitor.
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Clinical management
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prognosis
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prospective parents
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Molecular analysis:
identification of the
mutation
Assessment of
carrier statusis likely that non-Mendelian, multifactorial conditions modify
the natural history of HCM [21] which otherwise is, by defi-
nition, a Mendelian disorder. The difficulties of drawing firm
conclusions from knowledge of a mutation in a distinct
disease-related gene should not excuse a lack of compe-
tent genetic counselling. Counselling is more than mutation
detection. Appropriate activities depend on the existence
of an organisation comprising cardiologists, a molecular
laboratory, and clinical geneticists, as shown in the flow
diagram of Fig. 1. Such an organization is not everywhere
at hand. Since, however, knowledge and tools are in princi-
ple available, the appropriate answer to the initial question
of whether to provide genetic counselling “ready or not” is
that there is no good reason not to be ready.
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